What is claimed is:

1. A co-precipitate comprising cefuroxime axetil and a water-soluble excipient.

2. A co-precipitate as in claim 1 comprising from about 40% to about 98% by weight cefuroxime axetil and from about 2% to about 60% by weight water- soluble excipient.

3. A co-precipitate as in claim 1 comprising from about 75% to about 95% by weight cefuroxime axetil and from about 5% to about 25% by weight water-soluble excipient.

4. A co-precipitate as in claim 1 comprising about 90% by weight cefuroxime axetil and about 10% by weight water-soluble excipient.

5. A co-precipitate as in Claim 1 ~~any of claims 1 to 4~~ wherein the water-soluble excipient is selected from the group consisting of povidone, hydroxy propyl cellulose, methycellulose, lactose, mannitol and sorbitol.

6. A process of production of a co-precipitate of Claim 1 ~~any of claims 1 to 5~~ which comprises:-

- dissolving the cefuroxime axetil and water-soluble excipient in a solvent or a mixture of solvents; and
- evaporating the solvent or solvents.

7. A process as in claim 6 wherein acetone is used as solvent.

8. A process as in claim 6 wherein the solvent or solvents are evaporated by spray-drying.

9. A pharmaceutical tablet comprising a co-precipitate according to any of claims 1 to 5.

10. A pharmaceutical tablet as in claim 9 further comprising a disintegrant.

11. A pharmaceutical tablet as in claim 10 wherein the disintegrant is a water-insoluble cross-linked polymer.

12. A pharmaceutical tablet as in claim 10 wherein the disintegrant is selected from the group consisting of croscarmellose sodium, sodium starch glycolate and crospovidone.

13. A pharmaceutical tablet as in claim 10 further comprising a lubricant.

14. A pharmaceutical tablet as in claim 13 wherein the lubricant is stearic acid or a metallic stearate.